Amgen’s ‘Stunning’ VESALIUS Results Could Push Repatha Into The Mainstream

Global High-Risk Primary Prevention Market Is 100 Million Patients

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.